2 Bath Place
About Gyroscope TherapeuticsGyroscope Therapeutics is a private company founded by Syncona and Cambridge Enterprise and supported by its scientific founders with expertise in ophthalmology, immunology and gene therapy.
Our mission is to develop genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system.
Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative pharmaceutical companies.
April 16, 2016
Founders: Syncona and Cambridge Enterprise
CEO: Dr. Soraya Bekkali
Please click here for Gyroscope Therapeutics' job opportunities.
29 articles with Gyroscope Therapeutics
Novartis believes Gyroscope’s investigational Phase II gene therapy for geographic atrophy has the potential to become the first therapy that demonstrates sustained efficacy for GA patients.
11/10/2021Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here's who snagged funding this week.
Gyroscope Therapeutics Holdings plc today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44.5 million) in equity in Gyroscope.
It was a busy week for clinical trial news. Here’s a look.
Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids
Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company focused on treating diseases of the eye, announced the company has entered a research collaboration with Children’s Medical Research Institute in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies.
Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company focused on treating diseases of the eye, announced it has postponed plans for its initial public offering.
5/5/2021April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world.
Two weeks after announcing plans for initial public offerings, Gyroscope Therapeutics and Talaris Therapeutics have now set the terms for their debut on the Nasdaq.
Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced that it has launched the roadshow for its initial public offering in the United States of up to 6,750,000 American Depositary Shares (“ADSs”) representing 6,750,000 ordinary shares.
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.
Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States
Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.
3/31/2021Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye, announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States.
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye, announced it has raised USD $148.0 million in a Series C financing.
The financing involves Forbion’s Growth Opportunities Fund and includes its founding cornerstone investor, Syncona Investment Management Limited, which provided $42.3 million in investment.
3/5/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, announced the appointment of Jessica Stitt as Chief Financial Officer, effective immediately.
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
Interim Data Showed GT005 Was Well Tolerated in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Majority of Patients Treated with GT005 Had Increases in Complement Factor I (CFI) Levels, with an Average Increase of 146% Compared to Baseline Interim Data Demonstrated Potential for Single Administration of GT005 to Down-Regulate Overactive Complement System, a Key Driver of AMD
Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to Its Board of Directors
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately. “I am very pleased to welcome Jennifer, David, and Renée, three extremely accomplished executives with extensive biopharmaceutical backgrounds, to our board of directors,” said Khurem Farooq, Chief Executi
Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration
U.S. FDA Grants Second Fast Track Designation to GT005 for Treatment of Geographic Atrophy